Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)

NCT04322955 is registered in ClinicalTrials.gov with Mark Stein as lead sponsor.

NCT NCT04322955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04322955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)
Lead sponsor
Mark Stein
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 22, 2020
Completion date
February 29, 2028
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cell carcinoma